Community acquired bacterial pneumonia treatment drugs market

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, by Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, and Others), by Dose Form (Solution and Tablet), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Request Free Sample

Nov 2020
CMI4269
188 Pages
Excel & Pdf
Pharmaceutical

Summary

Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.

The global community-acquired bacterial pneumonia (CABP) treatment drugs market is estimated to be valued at US$ 1,269.73 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).

Figure 1. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Value (US$ Mn), by Region, 2020

The increasing prevalence of community-acquired pneumonia is expected to propel growth of the global community-acquired bacterial pneumonia (CABP) treatment drugs market

High prevalence of community-acquired pneumonia is expected to propel demand for community-acquired bacterial pneumonia (CABP) treatment drugs, which is expected to drive the market growth over the forecast period. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that the incidence of all?cause CAP each year was estimated at 0.81 per 1,000 individuals , rising to 6.95 per 1,000 person year in those aged 75 or older in Central Vietnam.

Moreover, increasing incidence of CAP were dominated by the effect of HIV. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that in 2017, the incidence of CAP were dominated by HIV if untreated, which was associated with a 17? to 35?fold increase in pneumococcal pneumonia in Sub-Saharan Africa region.

However, inappropriate treatment due to incorrect identification of pathogen contribute to the limited use of current drugs in the management of CABP. For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), the presence of multiple pathogens in patients leads to incorrect selection of initial antibiotic, which may affect the mortality outcome in CABP. Such inappropriate medication are expected to hamper the market growth.

Figure 2. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Share (%), by Drug Class, 2020

Increasing incidence of CAP in North America is expected to boost the market growth

North America is expected to hold dominant position in the global community-acquired bacterial pneumonia (CABP) treatment drugs market, owing to rising incidence of community-acquired pneumonia in the region especially in the U.S. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that in the U.S. overall incidence of community-acquired pneumonia in adults was around 2.5 per 1000 person, rising to 6.3 and 16.4 per 1000 person in adults aged 65-79 and 80 years or older in 2017. Furthermore, according to the Centers for Disease Control and Prevention (CDC), an article published in 2018 states that, around 6 million cases of community-acquired pneumonia were reported annually, resulting in an estimated 4.2 million ambulatory care visits, with adults age 65 and older most vulnerable to CAP.

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Report Coverage

Report Coverage	Details
Base Year:	2019	Market Size in 2020:	US$ 1,269.73 Mn
Historical Data for:	2016 to 2019	Forecast Period:	2020 to 2027
Forecast Period 2020 to 2027 CAGR:	7.2%	2027 Value Projection:	US$ 2,075.34 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, Others. By Dose Form: Solution, Tablet. By Route of Administration: Oral, Intravenous. By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:	Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.
Growth Drivers:	Increasing prevalence of community-acquired bacterial pneumonia Product launches amongst key players Robust product pipeline
Restraints & Challenges:	Inadequate penetration of antibacterial agents Antibiotic resistance in drugs

Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global community-acquired bacterial pneumonia (CABP) treatment drugs market during the forecast period.

Key Players

Major players operating in the global community-acquired bacterial pneumonia (CABP) treatment drugs market include Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.

Table of Content

Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
  - Nabriva Therapeutics
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Paratek Pharmaceuticals, Inc.
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Melinta Therapeutics, Inc.
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Allergan plc
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Bayer AG
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Lupin Pharmaceuticals, Inc.
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Mylan N.V.
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Sanofi S.A.
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Pfizer Inc.
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Dainippon Sumitomo Pharma
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Takeda Pharmaceutical Company Limited
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Basilea Pharmaceutica International AG
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Analyst Views
Section
- References
- Research Methodology
- About us and Sales Contact

*Browse 42 market data tables and 26 figures on "Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market” - Global forecast to 2027

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2020-2027)?

The global community-acquired bacterial pneumonia (CABP) treatment drugs market size is estimated to be valued at US$ 1,269.73 million in 2020 and is expected to exhibit a CAGR of 7.2% between 2020 and 2027.

What are the major drivers for community-acquired bacterial pneumonia (CABP) treatment drugs market growth?

The increasing prevalence of community-acquired bacterial pneumonia, product launches amongst key players, and robust pipeline of drugs are expected to favor the market growth.

Which is the leading by drug class segment in the global community-acquired bacterial pneumonia (CABP) treatment drugs market?

The pleuromutilin antibiotic segment is expected to be the leading drug class segment in the global community-acquired bacterial pneumonia (CABP) treatment drugs market during the forecast period (2020-2027).

Which region held the largest market share in the global community-acquired bacterial pneumonia (CABP) treatment drugs market?

North America community-acquired bacterial pneumonia (CABP) treatment drugs market is expected to generate highest revenue share during the forecast period.

Which are the major players operating in the global community-acquired bacterial pneumonia (CABP) treatment drugs market?

What is the estimated market size of the global community-acquired bacterial pneumonia (CABP) treatment drugs market in 2020?

The value of the global community-acquired bacterial pneumonia (CABP) treatment drugs market is estimated to be US$ 1,269.73 million in 2020.